Published in PLoS One on June 10, 2015
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development (2005) 8.42
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. Cells Tissues Organs (2007) 3.12
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell (2005) 2.65
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone (2002) 2.40
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol (2009) 1.67
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res (2008) 1.64
A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol (2002) 1.61
Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol (2012) 1.60
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol (2011) 1.60
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther (2010) 1.53
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate (2008) 1.42
Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev (2009) 1.40
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol (2009) 1.20
RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis (2006) 1.17
Role of p63 in cancer development. Biochim Biophys Acta (2011) 1.14
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res (2010) 1.10
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest (2000) 1.09
Biology and management of salivary gland cancers. Semin Radiat Oncol (2012) 1.09
Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res (2013) 1.08
RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08
Quiet mutations in inbred strains of mice. Trends Mol Med (2007) 1.05
The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett (2011) 1.01
RANKL/RANK - from bone physiology to breast cancer. Cytokine Growth Factor Rev (2014) 0.95
Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients. J Clin Periodontol (2008) 0.94
From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2011) 0.94
The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis (2010) 0.93
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Inbred mouse strains and genetic stability: a review. Animal (2011) 0.91
Association of salivary levels of the bone remodelling regulators sRANKL and OPG with periodontal clinical status. J Clin Periodontol (2012) 0.88
RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol (2011) 0.87
Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells (2013) 0.85
Recurrent salivary gland cancer. Curr Treat Options Oncol (2012) 0.85
Stem cells: Cues from steroid hormones. Nature (2010) 0.83
Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms. Cancer Lett (2008) 0.82
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol (2014) 0.81
Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. Pathology (2012) 0.81
The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Carcinogenesis (2011) 0.80
RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression. Am J Pathol (2011) 0.79
Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Oral Oncol (2012) 0.79
The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review). Int J Oncol (2013) 0.79
RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer. Am J Pathol (2013) 0.79
RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation. Oncol Rep (2011) 0.79
RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition. PLoS One (2014) 0.78
Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma. Odontology (2013) 0.77